<p>HC Wainwright 的研究分析師發佈了關於 Belite Bio（納斯達克股票代碼：BLTE）2025 年第一季度每股收益（EPS）的預估報告，預計公司將在本季度實現每股收益為（$0.29）。HC Wainwright 分析師 Y. Chen 預計，該公司全年每股收益的共識估值為（$1.08）。HC Wainwright 還預測了 Belite Bio 2025 年第二季度每股收益為（$0.29），第三季度每股收益為（$0.29），第四季度每股收益為（$0.29）。目前，HC Wainwright 給予該股票 “買入” 評級，並設定目標股價為$60.00。</p>
<p>其他幾家分析師最近也發佈了關於該公司的報告。Benchmark 在一份研究報告中重申了對 Belite Bio 的 “買入” 評級，並設定了$57.00 的目標股價。Cantor Fitzgerald 在 6 月 20 日星期四的一份研究報告中重申了對 Belite Bio 的 “超重” 評級。</p>
<p><strong>獲取我們關於 Belite Bio 的最新研究報告</strong></p>
<h2>Belite Bio 股價上漲 3.3%</h2>
<p>BLTE 股票週三開盤價為$50.16。該公司的市值為 14.9 億美元，市盈率為-42.51，貝塔係數為-1.47。Belite Bio 過去一年的最低股價為$20.32，最高股價為$50.66。該公司的 50 天簡單移動平均線為$48.43，200 天簡單移動平均線為$44.90。</p>
<p>Belite Bio（納斯達克股票代碼：BLTE）上次公佈季度財報是在 5 月 13 日星期一。該公司本季度每股收益為（$0.27），超過了（$0.34）的共識估值。</p>
<h2>對 Belite Bio 的對沖基金看法</h2>
<p>一家機構投資者最近在 Belite Bio 股票中建立了新頭寸。根據最近向美國證券交易委員會（SEC）披露的信息，Armistice Capital LLC 在去年第四季度收購了 Belite Bio，Inc（納斯達克股票代碼：BLTE）的新股份。該公司收購了該公司的 36,000 股股票，價值約 164.7 萬美元。截至最近一次向 SEC 提交的文件，Armistice Capital LLC 擁有 Belite Bio 約 0.13% 的股份。目前，0.53% 的股份由機構投資者和對沖基金持有。</p>
<h2>Belite Bio 公司簡介（獲取免費報告）</h2>
<p>Belite Bio，Inc 是一家臨牀階段的生物製藥藥物開發公司，致力於研究和開發針對美國未滿足醫療需求的視網膜退行性眼疾的新型治療藥物。該公司的主導產品候選藥物是 LBS-008（Tinlarebant），一種口服一日一次的片劑，用於維持常染色體隱性 Stargardt 病和地理性萎縮患者視網膜組織的健康和完整性。</p>
<h2>參見</h2>
<ul>
<li>我們喜歡的五支股票勝過 Belite Bio</li>
<li>爆發股票：是什麼以及如何識別</li>
<li>NVIDIA 股票在財報公佈前是否值得購買？</li>
<li>股票板塊對成功投資有何重要性？</li>
<li>Instacart 股票憑藉利潤和人工智能推動購物車發展勢頭</li>
<li>股票拆分意味着什麼？</li>
<li>PROCEPT BioRobotics 是否是外科機器人領域的下一個大事件？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和來自 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 在億萬富翁買光之前，先搶購這支 “人工智能燃料” 股票（來自市場後方）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4"/></p>
<h2>現在是否值得投資$1,000 在 Belite Bio？</h2>
<p>在考慮 Belite Bio 之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五支頂尖分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 Belite Bio 不在名單上。</p>
<p>儘管 Belite Bio 目前在分析師中有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

BLTE

<p>Belite Bio, Inc（納斯達克股票代碼：BLTE）收到了 HC Wainwright 對 2025 年第一季度盈利的預估，預計每股收益為{{.Question}}.29 美元，維持 “買入” 評級和目標股價為.00 美元。當前全年盈利的共識為（.08）美元每股。其他分析師，包括 Benchmark 和 Cantor Fitzgerald，重申了買入和超配評級。該股最近交易價為.16 美元，市值為.49 十億美元。Armistice Capital 最近收購了該公司的新股份，持有機構投資者持有的 0.53% 股份。Belite 專注於開發治療視網膜疾病的藥物</p>

<p>Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a &#34;Buy&#34; rating and a $60.00 price target on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.29) EPS.</p>
<div class="lb-trans"><p>HC Wainwright 的研究分析師發佈了關於 Belite Bio（納斯達克股票代碼：BLTE）2025 年第一季度每股收益（EPS）的預估報告，預計公司將在本季度實現每股收益為（$0.29）。HC Wainwright 分析師 Y. Chen 預計，該公司全年每股收益的共識估值為（$1.08）。HC Wainwright 還預測了 Belite Bio 2025 年第二季度每股收益為（$0.29），第三季度每股收益為（$0.29），第四季度每股收益為（$0.29）。目前，HC Wainwright 給予該股票 “買入” 評級，並設定目標股價為$60.00。</p>
</div><p>Several other analysts also recently issued reports on the company. Benchmark reiterated a &#34;buy&#34; rating and set a $57.00 price target on shares of Belite Bio in a research note on Tuesday. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Belite Bio in a research note on Thursday, June 20th.</p>
<div class="lb-trans"><p>其他幾家分析師最近也發佈了關於該公司的報告。Benchmark 在一份研究報告中重申了對 Belite Bio 的 “買入” 評級，並設定了$57.00 的目標股價。Cantor Fitzgerald 在 6 月 20 日星期四的一份研究報告中重申了對 Belite Bio 的 “超重” 評級。</p>
</div><p><strong>Get Our Latest Research Report on Belite Bio</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Belite Bio 的最新研究報告</strong></p>
</div><h2>Belite Bio Trading Up 3.3 %</h2>
<div class="lb-trans"><h2>Belite Bio 股價上漲 3.3%</h2>
</div><p>BLTE stock opened at $50.16 on Wednesday. The firm has a market cap of $1.49 billion, a PE ratio of -42.51 and a beta of -1.47. Belite Bio has a 1 year low of $20.32 and a 1 year high of $50.66. The company has a fifty day simple moving average of $48.43 and a 200 day simple moving average of $44.90.</p>
<div class="lb-trans"><p>BLTE 股票週三開盤價為$50.16。該公司的市值為 14.9 億美元，市盈率為-42.51，貝塔係數為-1.47。Belite Bio 過去一年的最低股價為$20.32，最高股價為$50.66。該公司的 50 天簡單移動平均線為$48.43，200 天簡單移動平均線為$44.90。</p>
</div><p>Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.07.</p>
<div class="lb-trans"><p>Belite Bio（納斯達克股票代碼：BLTE）上次公佈季度財報是在 5 月 13 日星期一。該公司本季度每股收益為（$0.27），超過了（$0.34）的共識估值。</p>
</div><h2>Hedge Funds Weigh In On Belite Bio</h2>
<div class="lb-trans"><h2>對 Belite Bio 的對沖基金看法</h2>
</div><p>An institutional investor recently bought a new position in Belite Bio stock. Armistice Capital LLC acquired a new stake in Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 36,000 shares of the company's stock, valued at approximately $1,647,000. Armistice Capital LLC owned about 0.13% of Belite Bio as of its most recent filing with the Securities and Exchange Commission (SEC). 0.53% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家機構投資者最近在 Belite Bio 股票中建立了新頭寸。根據最近向美國證券交易委員會（SEC）披露的信息，Armistice Capital LLC 在去年第四季度收購了 Belite Bio，Inc（納斯達克股票代碼：BLTE）的新股份。該公司收購了該公司的 36,000 股股票，價值約 164.7 萬美元。截至最近一次向 SEC 提交的文件，Armistice Capital LLC 擁有 Belite Bio 約 0.13% 的股份。目前，0.53% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Belite Bio Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Belite Bio 公司簡介（獲取免費報告）</h2>
</div><p>Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.</p>
<div class="lb-trans"><p>Belite Bio，Inc 是一家臨牀階段的生物製藥藥物開發公司，致力於研究和開發針對美國未滿足醫療需求的視網膜退行性眼疾的新型治療藥物。該公司的主導產品候選藥物是 LBS-008（Tinlarebant），一種口服一日一次的片劑，用於維持常染色體隱性 Stargardt 病和地理性萎縮患者視網膜組織的健康和完整性。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Belite Bio</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is NVIDIA Stock a Buy Ahead of Earnings?</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Instacart Stock Gains Momentum with Profits and AI-Powered Carts</li>
<li>What Does a Stock Split Mean?</li>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><h2>參見</h2>
<ul>
<li>我們喜歡的五支股票勝過 Belite Bio</li>
<li>爆發股票：是什麼以及如何識別</li>
<li>NVIDIA 股票在財報公佈前是否值得購買？</li>
<li>股票板塊對成功投資有何重要性？</li>
<li>Instacart 股票憑藉利潤和人工智能推動購物車發展勢頭</li>
<li>股票拆分意味着什麼？</li>
<li>PROCEPT BioRobotics 是否是外科機器人領域的下一個大事件？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=BLTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和來自 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Secure this &#34;AI Fuel&#34; Stock Before the Billionaires Buy It All (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 在億萬富翁買光之前，先搶購這支 “人工智能燃料” 股票（來自市場後方）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9148&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Belite Bio right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Belite Bio？</h2>
</div><p>Before you consider Belite Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Belite Bio 之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五支頂尖分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 Belite Bio 不在名單上。</p>
</div><p>While Belite Bio currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Belite Bio 目前在分析師中有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

HC Wainwright 發佈了 Belite Bio, Inc（納斯達克股票代碼：BLTE）2025 年第一季度的收益預測報告